Comparative Pharmacology
Head-to-head clinical analysis: PROCHLORPERAZINE MALEATE versus THIORIDAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCHLORPERAZINE MALEATE versus THIORIDAZINE HYDROCHLORIDE.
PROCHLORPERAZINE MALEATE vs THIORIDAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prochlorperazine is a phenothiazine antipsychotic that primarily antagonizes dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and central nervous system. It also has anticholinergic and antiemetic effects through blockade of histamine H1 and muscarinic M1 receptors.
Thioridazine is a typical antipsychotic of the phenothiazine class. It blocks postsynaptic dopamine D2 receptors in the mesolimbic system, and also has significant anticholinergic and alpha-adrenergic blocking activity. It exhibits a high affinity for D2, 5-HT2A, and alpha1-adrenergic receptors.
5-10 mg orally 3-4 times daily; or 25 mg rectally twice daily; or 5-10 mg intramuscularly every 3-4 hours up to 40 mg/day; or 2.5-10 mg intravenously slowly at 2.5 mg/min, maximum 20 mg/day.
Adults: Initial 50-100 mg orally three times daily, gradually increasing to maximum 800 mg/day in divided doses. Usual maintenance: 200-800 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults, but may extend up to 12-15 hours after chronic dosing or in hepatic impairment.
24-36 hours for the parent drug; extended in hepatic impairment and elderly; steady-state reached in 4-7 days.
Primarily renal (70-80% as metabolites, <1% unchanged); fecal/biliary excretion accounts for 20-30% via enterohepatic circulation.
Primarily hepatic metabolism with <1% excreted unchanged in urine; metabolites are excreted renally (approximately 30% of dose as metabolites) and fecally (approximately 20-30% via bile).
Category A/B
Category A/B
Typical Antipsychotic / Antiemetic
Typical Antipsychotic